循環器ジャーナル70巻1号

2022年01月発行

特集 心筋症診療のフロントライン—概念から最新の治療まで Ⅳ章　HFrEFと出会ったら

—重要な二次性DCM③—その他の二次性心筋症

著者： 尾上健児¹

所属機関： ¹奈良県立医科大学循環器内科

ページ範囲：P.72 - P.82

Point
・DCMが特発性（原発性）なのか二次性なのかを鑑別することが重要である．
・二次性心筋症では，病因に応じた治療法が病期の進行を抑制し，心機能改善にもつながる．

参考文献

1）日本循環器学会/日本心不全学会合同ガイドライン　心筋症診療ガイドライン（2018年改訂版）．2019年3月29日発行

2）Nakada Y, Kawakami R, Nakano T, et al : Sex differences in clinical characteristics and long-term outcome in acute decompensated heart failure patients with preserved and reduced ejection fraction. Am J Physiol Heart Circ Physiol 310 : H813-820, 2016

3）Templin C, Ghadri JR, Diekmann J, et al : Clinical features and outcomes of Takotsubo（stress）cardiomyopathy. N Engl J Med 373 : 929-938, 2015

4）Akashi YJ, Nef HM, Lyon AR : Epidemiology and pathophysiology of Takotsubo syndrome. Nat Rev Cardiol 12 : 387-397, 2015

5）Nakano T, Onoue K, Nakada Y, et al : Alteration of beta-Adrenoceptor Signaling in Left Ventricle of Acute Phase Takotsubo Syndrome : a Human Study. Sci Rep 8 : 12731, 2018

6）Attisano T, Silverio A, Prota C, et al : Impella in Takotsubo syndrome complicated by left ventricular outflow tract obstruction and severe mitral regurgitation. ESC Heart Fail 7 : 306-310, 2020

7）Mirijello A, Tarli C, Vassallo GA, et al : Alcoholic cardiomyopathy : What is known and what is not known. Eur J Intern Med 43 : 1-5, 2017

8）Barton JC, Edwards CQ : HFE hemochromatosis. GeneReviews［Internet］. University of Washington, Seattle. Initial Posting : April 3, 2000 ; Last Update : December 6, 2018.

9）Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines： The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology （ESC）. Eur Heart J 37 : 2768-2801, 2016

10）Lenneman CG, Sawyer DB : Cardio-Oncology : An Update on Cardiotoxicity of Cancer-Related Treatment. Circ Res 118 : 1008-1020, 2016

11）Lyon AR, Yousaf N, Battisti NML, et al : Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol 19 : e447-e458, 2018

12）Caforia ALP, Malipiero G, Marcolongo R, et al : Myocarditis : A Clinical Overview. Curr Cardiol Rep 19 : 63, 2017

13）Onoue K, Uemura S, Takeda Y, et al : Reduction of Circulating Soluble Fms-Like Tyrosine Kinase-1 Plays a Significant Role in Renal Dysfunction-Associated Aggravation of Atherosclerosis. Circulation 120 : 2470-2477, 2009

14）Seno A, Takeda Y, Matsui M, et al : Suppressed Production of Soluble Fms-Like Tyrosine Kinase-1 Contributes to Myocardial Remodeling and Heart Failure. Hypertension 68 : 678-687, 2016

15）Nakano T, Onoue K, Seno A, et al : Involvement of chronic inflammation via monocyte chemoattractant protein-1 in uraemic cardiomyopathy : a human biopsy study. ESC Heart Fail 8 : 3156-3167, 2021

16）Nakada Y, Onoue K, Nakano T, et al : AST-120, an Oral Carbon Absorbent, Protects against the Progression of Atherosclerosis in a Mouse Chronic Renal Failure Model by Preserving sFlt-1 Expression Levels. Sci Rep 9 : 15571, 2019

17）Grimaldi A, Mocumbi AO, Freers J, et al : Tropical Endomyocardial Fibrosis : Natural History, Challengers, and Perspectives. Circulation 133 : 2503-2515, 2016